Talis Biomedical Corporation TLIS
2.84
0.00
0.00%
as of 1 Apr
- Market cap
- $46.3M
- P/E
- 0.0×
Follow TLIS
Growth Flags
show if company had growth for consecutive years
| Jun '24 | Mar '24 | Dec '23 | Sep '23 | Older periods | |
|---|---|---|---|---|---|
| (70.48%) | (68.60%) | (63.32%) | (64.53%) |
+8 more TTM periods Free account |
|
| (52.13%) | (53.08%) | (46.98%) | (50.10%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(91.40%) | (90.34%) | (86.19%) | (89.41%) | |
Average Days of Receivables |
— | 2.21 | 8.55 | 0.83 | |
Free Cash Flow per Share |
(22.02) | (23.95) | (29.56) | (30.81) | |
Free Cash Flow |
(40.12) | (43.63) | (53.73) | (56.05) | |
Capital Expenditures |
0.14 | (0.43) | (0.49) | (0.63) | |
Piotroski F-Score |
— | 3.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(37.11%) | (34.01%) | (36.50%) | (32.69%) | |
Accounts Receivable Turnover |
— | 14.87 | 11.92 | 10.03 | |
Accounts Payable Turnover |
0.00 | 0.01 | 0.02 | 0.69 | |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 48,923.52 | 11,920.37 | 416.24 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 2,975.83% | 1,906.94% | 2,181.01% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 3,383.82% | 1,322.12% | 1,475.77% | |
Share Based Compensation of Revenue |
0.00% | 381.09% | 203.89% | 210.06% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.76 | 0.86 | 0.73 | |
Depreciation/Fixed assets |
1.82 | 0.53 | 0.25 | 1.24 | |
Capex/Depreciation |
0.18 | (0.50) | (0.63) | (0.15) | |
Revenue per Share |
0.00 | 0.54 | 1.17 | 1.21 | |
Operating CF per Share |
(22.09) | (23.71) | (29.29) | (30.47) | |
Capex per Share |
0.08 | (0.24) | (0.27) | (0.35) | |
Capex to Sales |
0.00 | 0.44 | 0.23 | 0.29 | |
Net Profit Margin |
0.00% | (5,784.73%) | (2,905.67%) | (3,436.98%) |
Columns are period end dates